Our Science

NEX-I, First-In-Class Cancer Immunotherapy Development Company

Pipeline

Project Target Indication Target market
position
Discovery Candidate
optimization
Pre-clinical Phase I/II
NXI-101
ONCOKINE-1
Solid Cancer
(NSCLC, TNBC, pancreatic, gastric cancer, etc.)
FIC
NXI-201
ONCOKINE-2
Solid Cancer
(Melanoma, CRC, etc.)
FIC
NXI-301
ONCOKINE-3
Solid Cancer
FIC
NXI-M01
Myeloid cells
Solid Cancer
FIC
NXI-C01
Undisclosed
Solid Cancer
FIC

*FIC : First-In-Class / *NSCLC : Non small cell lung cancer / *TNBC : Triple negative breast cancer / *CRC : Colorectal cancer